Treatment strategy for EGFR mutated NSCLC.

No abstract available

COI Statement

I have served on advisory boards for AstraZeneca or received speakers bureau fees from AstraZeneca, Chugai Pharma, Eli Lilly, Eisai, Ono Pharmaceutical, Takeda, and research grants to the institution from AstraZeneca, Merck Sharp & Dohme, and Summit Therapeutics.

Article info

Journal issue:

Volume: 13
Issue: 4

Doi:

10.1016/S2213-2600(25)00014-1

More resources:

Elsevier Science

Full Text Sources

Paid

NCI CPTC Antibody Characterization Program

Research Materials

Free resource

NCI CPTAC Assay Portal

Miscellaneous

Free resource

ClinicalKey

Full Text Sources

Paid